Search clinical trials for: BMS-986278

Total 3163 results

Bristol-Myers Squibb

Completed

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, Japan
Bristol-Myers Squibb

Terminated

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Advanced Solid Tumors

United States, Canada, United Kingdom
Bristol-Myers Squibb

Completed

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Advanced Malignancies

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Healthy Adult

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Diabetes

United States
Bristol-Myers Squibb

Completed

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

Atherosclerosis

Australia
Bristol-Myers Squibb

Completed

Multiple-Ascending Dose Study

Depression

Sweden
Bristol-Myers Squibb

Completed

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Netherlands, France, Italy, Belgium
Bristol-Myers Squibb

Terminated

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Hepatocellular Carcinoma

Canada, Singapore, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
Svelte Medical Systems Europe

Terminated

Acrobat Coronary Stent System Effectiveness European Study (ACES)

Coronary Artery Disease

Spain, France, Belgium
Bristol-Myers Squibb

Completed

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Hepatocellular Carcinoma

China
Bristol-Myers Squibb

Completed

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States, Germany, Australia, Canada, Japan, Latvia, Mexico, Poland
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Breast Cancer | Solid Tumor

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Study of Relatlimab in Combination With Nivolumab in Chinese Participants (RELATIVITY-111)

Advanced Solid Tumors

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Advanced Solid Tumors | Advanced B-cell NHL

United States, France, Spain, Germany
National Cancer Institute (NCI)

Terminated

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Terminated

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Canada
Oncoethix GmbH

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Pan Tumor

United States, Puerto Rico, Italy, Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Netherlands, Poland, Romania, Singapore, Spain, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)

Renal Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostrate Cancer

United States
Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)

France, Korea, Republic of, Taiwan, United States, Singapore, Philippines, Malaysia, Hong Kong
Bristol-Myers Squibb

Completed

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, United States, Australia
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Chronic Hepatitis C

United States, Argentina
Bristol-Myers Squibb

Terminated

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Hypercholesterolemia

Germany, Canada
Leonardo Bolognese, MD

Terminated

A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation (ELICOPTER)

Myocardial Ischemia

Italy
Georgetown University
Bristol-Myers Squibb; M.D. Anderson Cancer Center; University of Colorado, Denver and other collaborators

Terminated

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma | Acral Lentiginous Melanoma

United States
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)

Kidney Neoplasms

India
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Healthy Adult Normals

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

Cancer (Solid Tumors)

United Kingdom, United States, Canada
Bristol-Myers Squibb

Terminated

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Advanced Solid Tumors

United States, Netherlands

3

Subscribe